The Role of CETP Inhibition in Dyslipidemia

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2007 Sep 20

PMID 17877921

Citations 6

Authors

Karim El Harchaoui

Wim A van der Steeg

Erik S G Stroes

John J P Kastelein

Affiliations

Soon will be listed here.

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.

Citing Articles

Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults.

Kim J, Shin S, Kim Y, Kang H Cardiovasc Diabetol. 2021; 20(1):183.

PMID: 34503545 PMC: 8431895. DOI: 10.1186/s12933-021-01377-5.

Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis.

Zhang T, Chen J, Tang X, Luo Q, Xu D, Yu B Lipids Health Dis. 2019; 18(1):223.

PMID: 31842884 PMC: 6913018. DOI: 10.1186/s12944-019-1170-9.

Subcutaneous Adipocyte Lipolysis Contributes to Circulating Lipid Levels.

Ryden M, Arner P Arterioscler Thromb Vasc Biol. 2017; 37(9):1782-1787.

PMID: 28663255 PMC: 5567402. DOI: 10.1161/ATVBAHA.117.309759.

The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles.

Trevaskis N, Shanker R, Charman W, Porter C Pharm Res. 2010; 27(9):1949-64.

PMID: 20635194 DOI: 10.1007/s11095-010-0199-2.

The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623).

Trevaskis N, McEvoy C, McIntosh M, Edwards G, Shanker R, Charman W Pharm Res. 2010; 27(5):878-93.

PMID: 20221896 DOI: 10.1007/s11095-010-0083-0.

References

Kassai A, Illyes L, Mirdamadi H, Seres I, Kalmar T, Audikovszky M . The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem. 2006; 40(1-2):1-5. DOI: 10.1016/j.clinbiochem.2006.05.016. View

Passarelli M, Catanozi S, Nakandakare E, Rocha J, MORTON R, Shimabukuro A . Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia. 1997; 40(9):1085-93. DOI: 10.1007/s001250050791. View

Dullaart R, Hoogenberg K, Dikkeschei B, van Tol A . Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb. 1994; 14(10):1581-5. DOI: 10.1161/01.atv.14.10.1581. View

Mann C, Yen F, Grant A, Bihain B . Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991; 88(6):2059-66. PMC: 295801. DOI: 10.1172/JCI115535. View

Matsuura F, Wang N, Chen W, Jiang X, Tall A . HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006; 116(5):1435-42. PMC: 1451209. DOI: 10.1172/JCI27602. View

Le N, Li X, Black D, Brown W . Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 2000; 49(2):167-77. DOI: 10.1016/s0026-0495(00)91169-7. View

Bisoendial R, Hovingh G, Harchaoui K, Levels J, Tsimikas S, Pu K . Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005; 25(9):e133-4. DOI: 10.1161/01.ATV.0000179009.60612.28. View

Boekholdt S, Kuivenhoven J, Wareham N, Peters R, Jukema J, Luben R . Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation. 2004; 110(11):1418-23. DOI: 10.1161/01.CIR.0000141730.65972.95. View

Bagdade J, Ritter M, Subbaiah P . Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest. 1991; 87(4):1259-65. PMC: 295149. DOI: 10.1172/JCI115127. View

10.

Durrington P, Mackness M, Bhatnagar D, Julier K, Prais H, Arrol S . Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis. 1998; 138(1):217-25. DOI: 10.1016/s0021-9150(98)00003-3. View

11.

Quintao E, Medina W, Passarelli M . Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev. 2000; 16(4):237-50. DOI: 10.1002/1520-7560(200007/08)16:4<237::aid-dmrr127>3.0.co;2-9. View

12.

Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch J . Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med. 2006; 260(2):151-9. DOI: 10.1111/j.1365-2796.2006.01674.x. View

13.

Le Goff W, Guerin M, Chapman M . Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004; 101(1):17-38. DOI: 10.1016/j.pharmthera.2003.10.001. View

14.

de Grooth G, Kuivenhoven J, Stalenhoef A, de Graaf J, Zwinderman A, Posma J . Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002; 105(18):2159-65. DOI: 10.1161/01.cir.0000015857.31889.7b. View

15.

Watts G, Ji J, Chan D, Ooi E, Johnson A, Rye K . Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (Lond). 2006; 111(3):193-9. DOI: 10.1042/CS20060072. View

16.

Guerin M, Lassel T, Le Goff W, Farnier M, Chapman M . Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000; 20(1):189-97. DOI: 10.1161/01.atv.20.1.189. View

17.

Hannuksela M, Marcel Y, Kesaniemi Y, Savolainen M . Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res. 1992; 33(5):737-44. View

18.

Doggrell S . Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease. Expert Opin Investig Drugs. 2006; 15(2):99-106. DOI: 10.1517/13543784.15.2.99. View

19.

Tato F, Vega G, Tall A, Grundy S . Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1995; 15(1):112-20. DOI: 10.1161/01.atv.15.1.112. View

20.

Birjmohun R, Hutten B, Kastelein J, Stroes E . Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005; 45(2):185-97. DOI: 10.1016/j.jacc.2004.10.031. View